Teva Defense Verdict — What It Means for Paragard Cases

The Rickard v. Teva Trial — What Happened

On February 5, 2026, the jury in Rickard v. Teva Pharmaceuticals USA, Inc. — the first bellwether trial in MDL 2974 — returned a verdict for Teva on all counts. Plaintiff Pauline Rickard had alleged that her Paragard IUD broke during removal in 2018, causing injury that required surgical intervention, and that Teva failed to warn patients and providers of the device's propensity for arm fracture. After a multi-week trial in Atlanta before Judge Leigh Martin May, the jury rejected plaintiff's failure-to-warn and defective design theories. Teva's key arguments were: (1) Paragard's prescribing information disclosed the risk of arm breakage during removal; (2) the plaintiff's provider's removal technique, rather than the device design, was a contributing cause; and (3) the plaintiff failed to establish that a stronger warning would have changed her or her provider's decision to use Paragard.

What the Defense Verdict Means — and What It Doesn't

The Rickard defense verdict means that the specific jury who evaluated Pauline Rickard's specific case found for Teva. It does not mean that all Paragard cases will lose. Each case in an MDL is evaluated on its own facts, and plaintiffs with stronger fact patterns — particularly clear imaging documentation of fragment retention, multiple major surgeries, and infertility — are meaningfully distinguished from the Rickard case. The defense verdict will likely give Teva greater leverage in global settlement negotiations for lower-tier cases, but it increases the importance of aggressive medical record development and expert testimony for cases in the top injury tiers. Women who suffered infertility, hysterectomy, or major organ damage should not be deterred from pursuing their claims.

Comparable MDL Defense Verdicts — History Shows Recovery Is Possible

Large medical device and pharmaceutical MDLs routinely produce defense verdicts in early bellwether trials. The 3M Combat Arms Earplug MDL saw numerous defense verdicts before a $6 billion settlement. Bayer's Essure MDL produced defense wins before meaningful resolution. In each of these cases, a single defense verdict did not end the litigation — it refined the plaintiff's bar's approach, strengthened subsequent case presentations, and ultimately contributed to a settlement framework that compensated injured claimants. The MDL process is designed to use bellwether trials — including defense verdicts — as data points for both sides. The March and May 2026 bellwether trials will provide those additional data points for Paragard.

Should I Still File After the Defense Verdict?

Yes — if your Paragard broke, you required surgery, and you suffered significant injury, you should still consult an attorney and file a claim if your statute of limitations has not expired. The Rickard defense verdict does not bar your claim or eliminate your right to compensation. MDL 2974 is ongoing. Two more bellwether trials are forthcoming. Settlement negotiations between the parties continue. The critical action item is not waiting: the 2025 breakage-date ruling means statutes of limitations are actively running from your Paragard removal date. Waiting to see how subsequent bellwether trials unfold risks your statute of limitations expiring while the MDL continues. File now, preserve your rights, and let the litigation process play out while your claim is protected.